Dark

LIXT
Lixte Biotechnology Holdings, Inc. Common Stock
stock NASDAQ

Market Open

Jul 30, 2025 12:06:23 PM EDT

3.70USD-3.394%(-0.13)53,568

3.65Bid 3.70Ask 0.05Spread

Pre-market

Jul 28, 2025 8:18:30 AM EDT

4.07USD+6.266%(+0.24)0

After-hours

Jul 29, 2025 4:43:30 PM EDT

3.77USD-1.823%(-0.07)0

OverviewHistoricalExchangesShortsNews

Jan 28, 2022

12:43PM EST Lixte Biotechnology To Be Issued U.S. Patent Titled 'OXABICYCLOHEPTANE PRODRUGS' On Feb. 1 Benzinga

Jan 12, 2022

08:33AM EST Lixte Biotechnology Announces Filing Of First Patent Application Resulting From Collaboration With the Netherlands Cancer Institute And The Oncode Institute To Identify The Most Promising Drug Combinations For Lead Clinical Compound, LB-100 Benzinga

08:30AM EST Lixte Biotechnology Announces Filing of First Patent Application GlobeNewswire Inc

Jan 10, 2022

07:41AM EST The Week Ahead In Biotech (Jan 10-15): JPMorgan Healthcare Conference Front And Center, Preannouncements Keep Coming Benzinga

Jan 5, 2022

08:37AM EST Lixte Biotechnology's LB-100 Reported To Convert Immunologically Unresponsive Tumors To Immunologically Responsive Tumors Benzinga

08:30AM EST Outside research shows that in models of colorectal, triple-negative breast and pancreatic cancer,LB-100 induces molecular changes that render the cancers more vulnerable to immunotherapy GlobeNewswire Inc

Nov 22, 2021

09:26AM EST Lixte Biotechnology Holdings, Inc. Announces That Enrollment Has Resumed In National Cancer Institute's Trial To Determine Ability Of Lixte Compound LB-100 To Enter Recurrent, Malignant Brain Tumors Benzinga

09:25AM EST LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS GlobeNewswire Inc

Oct 28, 2021

12:21PM EDT From Benzinga Small Cap Conference: Lixte Biotech Holdings CEO Highlights Collaboration With Netherlands Cancer Institute Benzinga

12:13PM EDT From Benzinga Small Cap Conference: Lixte Biotech Holdings CEO Says Small Cell Lung Cancer Is Ideal Testing Candidate Benzinga

12:08PM EDT From Benzinga Small Cap Conference: Lixte Biotech Holdings CEO Highlights Pipeline For LB-100 Benzinga

12:02PM EDT From Benzinga Small Cap Conference: Lixte Biotech Holdings CEO John Kovach Begins Presentation Benzinga

Oct 20, 2021

09:25AM EDT Studies to use genome wide functional genetic techniques to identify effective drug combinations and new drug targets for its lead clinical compound, LB-100 GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT Lixte Biotechnology Announces Collaboration With Netherlands Cancer Institute, Oncode Institute To 'Identify The Most Promising Drug Combinations For Its Lead Clinical Compound, LB-100, For Cancer Treatment' Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 1, 2021

01:23PM EDT Lixte Biotechnology Granted European Patent Titled 'CLINICAL REGIMEN FOR TREATING MYELODYSPLASTIC SYNDROME WITH PHOSPHATASE INHIBITOR' Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

11:02AM EDT Lixte's LB-100 Blocks Behavioral Sensitization In Animal Models Benzinga

09:29AM EDT Lixte Biotech Reports Pre-Clinical Studies In Its Lead Clinical Compound, LB-100, Reduced Behavioral Sensitization Underlying Addiction To Methamphetamine Benzinga

09:25AM EDT A seriesof recent pre-clinical reports demonstrates LB-100s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition GlobeNewswire Inc

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 3, 2021

02:51PM EDT Lixte Biotech shares were trading higher after the company announced its lead clinical compound, LB-100, was reported to enhance the effectiveness of elements of standard therapy in models of small cell lung cancer. Benzinga

12:35PM EDT Mid-Morning Market Update: Markets Down; Alibaba Posts Downbeat Q1 Sales Benzinga

12:12PM EDT Mid-Day Market Update: Crude Oil Down 2%; Arcturus Therapeutics Shares Spike Higher Benzinga

10:15AM EDT Mid-Morning Market Update: Markets Down; Alibaba Posts Downbeat Q1 Sales Benzinga

09:25AM EDT Lixte Reports Its LB-100 Elicits Anti-Tumor Activity In Small Lung Cancer Models Benzinga

09:25AM EDT A Pre-Clinical Study Reports that LB-100 Potentiates Standard Therapy for Small Cell Lung Cancer Providing a Strong Rationalefor a Clinical Trial of LB-100 in Small Cell Lung Cancer Recently Initiated at City of Hope. GlobeNewswire Inc

Jul 22, 2021

09:27AM EDT UPDATE: Lixte Says 'vosoritide (BioMarin), was even more effective than vosorotide alone in stimulating bone length and cartilage area in a mouse model of the most common form of dwarfism' Benzinga

09:26AM EDT Lixte Biotech Issues Comment On Report Its Protein Phosphatase 2A Inhibitor Combined With Another Investigational Agent Stimulates Bone Growth In Models Of Dwarfism Benzinga

09:25AM EDT LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR GlobeNewswire Inc

Jul 13, 2021

09:27AM EDT Lixte Biotechnology Comments on Outside Research Citing GlobeNewswire Inc

Jul 7, 2021

09:40AM EDT Lixte Biotech Shares Quiet Following Press Release Highlighting Presentation Its Drug Development For Cancer Treatment At TheMoneyShow Virual Expo On Jul. 14, 2021 At 3:20 p.m. EDT Benzinga

09:35AM EDT Presentation to highlight Companys current clinical study of lead compound LB-100 for Small Cell Lung Cancer GlobeNewswire Inc

Jun 3, 2021

08:22AM EDT A Breakthrough in Targeted Cancer Therapy: Lixte Biotechnology Clinical Stage Compound LB-100 Benzinga

Jun 2, 2021

09:39AM EDT Lixte Biotechnology, City Of Hope Enroll First Patient In Phase 1b Trial Of Lead Compound LB-100 For Treatment Of Small Cell Lung Cancer Benzinga

09:35AM EDT -- Extensive preclinical data shows LB-100 increases the effectiveness of chemotherapy in animal models -- Due to the aggressive progression of small cell lung cancer, it is possible that therapeutic benefit in patients may be seen in this early-stage clinical trial GlobeNewswire Inc

May 25, 2021

11:09AM EDT Lixte Biotech Holdings Granted Canadian Patent Titled 'FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES' Benzinga

May 13, 2021

01:21PM EDT From BZ Global Small-Cap Conference: Lixte Biotech CEO Says Co Currently Has $7 Million In Cash, But Still Looking For Raising Some Extra Cash To Finance Its Trials Benzinga

01:11PM EDT From BZ Global Small-Cap Conference: Lixte Biotech CEO Talks About Phase 1b Trial In Advanced Small Cell Lung Cancer; Notes, Co Expects To Enroll 30 Patients And The Duration Will Be 24-36 Months Benzinga

01:08PM EDT From BZ Global Small-Cap Conference: Lixte Biotech CEO Says Co Is Now Focusing On To Demonstrate In One Or More Cancers That LB-100 Significantly Improves Benzinga

01:06PM EDT From BZ Global Small-Cap Conference: Lixte Biotech CEO Says The Co Is Now The Leader In Evaluating Of Effectiveness of PP2A Inhibition For Cancer Therapy Benzinga

01:03PM EDT From BZ Global Small-Cap Conference: Lixte Biotech CEO Says Co is Not Aware Of Any Competition, But The Co Eventually Expects Some Competitors Benzinga

01:02PM EDT From BZ Global Small-Cap Conference: Lixte Biotech CEO Talks About A Breakthrough In Cancer Therapy Benzinga

01:01PM EDT Lixte Biotech CEO Begins Presentation During Benzinga's Global Small Cap Conference Benzinga

May 12, 2021

09:35AM EDT Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as an independent director and audit committee chair. GlobeNewswire Inc

Apr 28, 2021

09:37AM EDT Lixte Biotechnology Says To Discuss Pipeline Of Clinical Investigations For 4 Cancer Targets At Benzinga Global Small Cap Conference Being Held May 13-14 Benzinga

09:35AM EDT -- Lixtes pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100 GlobeNewswire Inc

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 20, 2021

10:49AM EDT Novel Approach to Cancer From Lixte Biotechnology Could Be a General way to Enhance a Variety of Standard Treatments Benzinga

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

Apr 15, 2021

07:49AM EDT The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 13, 2021

09:35AM EDT Lixte Biotechnology Holdings, Inc. (Lixte or the Company) (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of Gil N Schwartzberg to its Board of Directors. Mr. Schwartzberg is filling a vacancy created by the resignation of Winson (Sze Chun) Ho, M.D. GlobeNewswire Inc

Mar 25, 2021

02:45PM EDT Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference Benzinga

Mar 24, 2021

11:09AM EDT From Benzinga Small Cap Conference, Lixte Biotechnology CEO, John S. Kovac Says The Co Is In The Process Of Preparing A New Drug Inventory In Europe Benzinga

11:07AM EDT From Benzinga Small Cap Conference, Lixte Biotechnology CEO, John S. Kovac Says In The Next 12 Months The Co Will Complete Of Its Phase 1b Of The MDS Trial And The NCI Glioma Human Pharmacology Trial. Benzinga

11:03AM EDT From Benzinga Small Cap Conference, Lixte Biotechnology CEO, John S. Kovac Says The Co's Goal Is To Demonstrate In One Or More Cancers That LB-100 Significantly Improves The Outcomes Of Patients Benzinga

11:00AM EDT From Benzinga Small Cap Conference, Lixte Biotechnology CEO, John S. Kovac Says Most Cancer Research In The Past 30 Years On The "On" Switches (Kinases) Benzinga

10:59AM EDT From Benzinga Small Cap Conference, Lixte Biotechnology CEO, John S. Kovac Says The Co Is Not Aware Of Any Competition Benzinga

10:58AM EDT From Benzinga Small Cap Conference, Lixte Biotechnology CEO, John S. Kovac Says The Co Has Created And Patented A Series Of Novel Drugs Benzinga

Mar 23, 2021

07:12PM EDT Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021 Benzinga

Mar 17, 2021

09:36AM EDT Lixte Biotechnology Says To Present Novel Product Candidate For Targeted Cancer Therapy At Benzinga Biotech Small Cap Conference On March 24 Benzinga

09:35AM EDT -- More than 40 preclinical studies have found that Lixtes lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity GlobeNewswire Inc

Mar 3, 2021

09:37AM EST Lixte Biotechnology Says Will Showcase Anti-Cancer Therapy Enhancer LB-100 At Virtual ROTH Capital Conference Benzinga

09:35AM EST -- LB-100 is Currently in Clinical Studies for Four Cancer Targets: Phase 1b/2 for Myelodysplastic (MDS) SyndromesPhase 1b/2 for Advanced Soft Tissue SarcomaPhase 0 (Pharmacodynamics) for Glioblastoma MultiformePhase 1b for Small Cell Lung CancerPre-clinical for Angelman Syndrome GlobeNewswire Inc

Mar 2, 2021

06:38PM EST WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) Business Wire

03:42PM EST WallachBeth Capital Announces Completion of $4.19 Million Registered Direct PR Newswire

10:30AM EST Lixte Biotechnology Announces the Closing of $4.19 Million GlobeNewswire Inc

Mar 1, 2021

08:46AM EST Lixte Biotechnology Announces $4.19M Registered Direct Offering; 1,133,102 Shares At $3.70/Share Benzinga

08:45AM EST Lixte Biotechnology Announces $4.19 Million Registered Direct Offering GlobeNewswire Inc

Feb 26, 2021

02:50PM EST Mid-Afternoon Market Update: Crude Oil Down Over 3%; AMC Networks Shares Surge After Q4 Results Benzinga

12:17PM EST Mid-Day Market Update: Nasdaq Rises Over 100 Points; Recro Pharma Shares Plummet Benzinga

10:21AM EST Mid-Morning Market Update: Markets Mostly Lower; Foot Locker Reports Mixed Q4 Results Benzinga

09:58AM EST Shares of Lixte Biotechnology Holdings Inc. (LIXT) are surging over 55% on Friday morning despite no stock-related news to drive the shares. RTTNews

08:56AM EST Benzinga Pro's Top 5 Stocks To Watch For Friday, Feb. 26, 2021: RKT, NGA, GM, EBON, LIXT Benzinga

Feb 24, 2021

09:38AM EST Lixte Biotech (Very Light Volume Issue) Reports Will Present Its Anti-Cancer Therapy Enhancer At HC Wainwright Global Life Sciences Conference Being Held Mar. 9-10, 2021 Benzinga

Jan 26, 2021

12:06PM EST Lixte Biotechnology Files For Mixed Shelf Of Up To $20M Benzinga

Jan 19, 2021

10:24AM EST Shares of clinical-stage drug discovery company Lixte Biotechnology Holdings, Inc. (LIXT) are rising more than 15% Tuesday morning after the company announced an agreement with cancer research and treatment center, City of Hope to begin Phase 1b study of LB-100 in small cell lung cancer. RTTNews

09:35AM EST Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical GlobeNewswire Inc

Dec 30, 2020

08:16AM EST The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga

Dec 9, 2020

01:44PM EST Lixte Biotechnology Granted Eurpean Patent Number EP3258930 Titled 'OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS' Benzinga

Dec 8, 2020

05:24AM EST Gil Schwartzberg Reported Purchase of 210,528 Shares of Lixte Biotechnology Holdings, Inc. @ Avg Price of $4.75/ Share in Form 4 Filing on Monday Benzinga

Dec 1, 2020

03:29PM EST WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten PR Newswire

12:30PM EST Lixte Biotechnology Holdings, Inc. Announces Closing of Public GlobeNewswire Inc

Nov 30, 2020

03:52PM EST WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW) Business Wire

Nov 25, 2020

08:30AM EST Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 GlobeNewswire Inc

Aug 18, 2020

09:35AM EDT The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte GlobeNewswire Inc

Jul 21, 2020

09:35AM EDT Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) today announced the appointment of Dr. James Miser as its Chief Medical Officer commencing August 1, 2020. GlobeNewswire Inc

.dark-mode .WTRgx9{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .WTRgx9{ color: #333333; background-color: white; border: 2px solid #333333; }LIXTLixte Biotechnology Holdings, Inc. Common Stockstock NASDAQ

LIXT
Lixte Biotechnology Holdings, Inc. Common Stock
stock NASDAQ